TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyUnique sublingual formulation ...
Some common dietary supplements can raise blood pressure, especially if you already have high blood pressure or heart ...
WhiteSands Alcohol & Drug Rehab Orlando has published a new educational resource focused on treatment considerations during the Zoloft withdrawal timeline, addressing a topic that affects many ...
The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...
Pharmaceutical Technology on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
MedPage Today on MSN
Next DSM insights; FDA reviewing non-stimulant ADHD drug; 10M people microdosing
News and commentary from the psychiatry world ...
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results